SCHEMBL1136719

SCHEMBL1136719

NC1CCN(C(=O)c2ccc(C(=O)N3CCC(N)CC3)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 12/20 0.59
L3MBTL1 Q9Y468 8/20 0.59
MBTD1 Q05BQ5 4/20 0.59
TP53BP1 Q12888 1/20 0.59
L3MBTL4 Q8NA19 1/20 0.59
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
ACHE P22303 1/20 0.55
MAPT P10636 1/20 0.54
HSD11B1 P28845 1/20 0.54
MGLL Q99685 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA14 Q9ULX7 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1136918 0.98 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
Bromide SCHEMBL1136932 0.98 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL23775674 0.93 MGLL (0.59) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL13575475 0.93 MGLL (0.61) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL647507 0.91 MGLL (0.69) ALDH1A1HPGDMAPTHSD11B1MGLL
SCHEMBL17277458 0.91 KMT2A (0.69) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4399941 0.91 HSD11B1 (0.69) L3MBTL1ALDH1A1HSD11B1MGLLMEN1
SCHEMBL409005 0.90 ACHE (0.69) L3MBTL3L3MBTL1ALDH1A1HPGDACHE
Hydrochloric Acid SCHEMBL4617268 0.89 HSD11B1 (0.67) L3MBTL1ALDH1A1HSD11B1MGLLMEN1
Hydrochloric Acid SCHEMBL4618202 0.89 ACHE (0.67) L3MBTL3L3MBTL1ALDH1A1HPGDACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318935-B2 Organic compounds 75074 NOVARTIS AG (CH) 2012-11-27 US disclosed
EP-2332933-A1 Epithelial sodium channel (ENaC) inhibitors Novartis AG (CH) 2011-06-15 EP disclosed
EP-2155721-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-23 EP disclosed
US-20100105660-A1 ORGANIC COMPOUNDS75074 NOVARTIS AG (CH) 2010-04-29 US disclosed
EP-2155721-A1 ORGANIC COMPOUNDS Novartis Ag (CH) 2010-02-24 EP disclosed
WO-2008135557-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105660-A1 ORGANIC COMPOUNDS75074 SCNN1A, TRPM4, TRPV4 L3MBTL3 2819/4885L3MBTL1 2603/4885MBTD1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.